Literature DB >> 24596032

Genetic association between ERCC5 rs17655 polymorphism and lung cancer risk: evidence based on a meta-analysis.

Yujia Liang1, Jun Deng, Ying Xiong, Songping Wang, Wei Xiong.   

Abstract

The relationship between excision repair cross-complementing group 5 (ERCC5) rs17655 polymorphism and lung cancer risk remains controversial. To clarify the association, we conducted a comprehensive meta-analysis of all published case-control studies. PubMed, Web of Science, and CNKI were searched to identify the possibly eligible publications. Pooled odds ratio (OR) was estimated using the fixed effect model. Q test and I (2) index were used to evaluate heterogeneity between studies, and Egger's and Begg's tests were utilized to assess publication bias. Meta-analysis of nine case-control studies including 4,044 cases and 5,100 controls indicated that there was no global association between rs17655 polymorphism and lung cancer risk. Subgroup analyses according to ethnicity and histologic type revealed similar results. In summary, our meta-analysis suggests that ERCC5 rs17655 polymorphism may not contribute to genetic susceptibility for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24596032     DOI: 10.1007/s13277-014-1742-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Germ line variation in nucleotide excision repair genes and lung cancer risk in smokers.

Authors:  Lori C Sakoda; Melissa M Loomis; Jennifer A Doherty; Liberto Julianto; Matt J Barnett; Marian L Neuhouser; Mark D Thornquist; Noel S Weiss; Gary E Goodman; Chu Chen
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-05

Review 3.  Human DNA repair systems: an overview.

Authors:  Z Yu; J Chen; B N Ford; M E Brackley; B W Glickman
Journal:  Environ Mol Mutagen       Date:  1999       Impact factor: 3.216

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Polymorphisms of XPG/ERCC5 and risk of squamous cell carcinoma of the head and neck.

Authors:  Hongxia Ma; Hongping Yu; Zhensheng Liu; Li-E Wang; Erich M Sturgis; Qingyi Wei
Journal:  Pharmacogenet Genomics       Date:  2012-01       Impact factor: 2.089

6.  Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk.

Authors:  Tokuki Sakiyama; Takashi Kohno; Sachiyo Mimaki; Tsutomu Ohta; Noriko Yanagitani; Tomotaka Sobue; Hideo Kunitoh; Ryusei Saito; Kimiko Shimizu; Chie Hirama; Junko Kimura; Go Maeno; Hiroshi Hirose; Takashi Eguchi; Daizo Saito; Misao Ohki; Jun Yokota
Journal:  Int J Cancer       Date:  2005-05-01       Impact factor: 7.396

Review 7.  Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer.

Authors:  Toralf Bernig; Stephen J Chanock
Journal:  Expert Rev Mol Diagn       Date:  2006-05       Impact factor: 5.225

8.  Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.

Authors:  Florence Koeppel; Virginie Poindessous; Vladimir Lazar; Eric Raymond; Alain Sarasin; Annette K Larsen
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

9.  CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions.

Authors:  E L Crawford; T Blomquist; D N Mullins; Y Yoon; D R Hernandez; M Al-Bagdhadi; J Ruiz; J Hammersley; J C Willey
Journal:  Carcinogenesis       Date:  2007-09-24       Impact factor: 4.944

Review 10.  DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis.

Authors:  Carol Bernstein; Harris Bernstein; Claire M Payne; Harinder Garewal
Journal:  Mutat Res       Date:  2002-06       Impact factor: 2.433

View more
  5 in total

1.  Association between ERCC5 gene polymorphisms and breast cancer risk.

Authors:  Nari Na; Eer Dun; Lidong Ren; Guoxin Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  An insight into clinical outcome of XPG polymorphisms in breast cancer.

Authors:  Saima Shakil Malik; Sumaira Mubarik; Nosheen Masood; Muhammad Tahir Khadim
Journal:  Mol Biol Rep       Date:  2018-09-25       Impact factor: 2.316

3.  Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.

Authors:  Jianfang Chen; Xi Luo; Ganfeng Xie; Keli Chen; Heng Jiang; Feng Pan; Jianjun Li; Zhihua Ruan; Xueli Pang; Houjie Liang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

4.  XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.

Authors:  Fang Wang; Shao-Dan Zhang; Hong-Mei Xu; Jin-Hong Zhu; Rui-Xi Hua; Wen-Qiong Xue; Xi-Zhao Li; Tong-Min Wang; Jing He; Wei-Hua Jia
Journal:  Oncotarget       Date:  2016-03-08

5.  XPG rs17655 G>C polymorphism associated with cancer risk: evidence from 60 studies.

Authors:  Jie Zhao; Shanshan Chen; Haixia Zhou; Ting Zhang; Yang Liu; Jing He; Jinhong Zhu; Jichen Ruan
Journal:  Aging (Albany NY)       Date:  2018-05-20       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.